Technology

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

How pharma firms assess their readiness for IDMP (Identification of Medicinal Products) is important for meeting compliance requirements and ensuring they are prepared for the digital product information management future, writes Adnan Jamil.

Emerging pharmaceutical technologies can aid in rapid drug and vaccine development — but only if pharma companies prioritize digitization initiatives.

How the UK is making progress in this hi-tech field.

Coordination of KOL engagement is all but impossible if the information an organization collects about them is fragmented. What is needed is a centralized database that captures all information about an expert from the multiple touch points across functions and geographies.

Developing a diversity mindset may begin at the top levels of the organization, but building diversity into the entire drug development life cycle ensures that it is an ongoing priority and a natural requirement of engaging with external stakeholders.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.

Amgen is collaborating on two digital health initiatives aimed at improving heart failure care and rehabilitation.

Exposing the truth behind AI myths highlighted by COVID.

Treating medical affairs solely as a support function is penny-wise and pound foolish. With the advent of machine learning, the medical affairs team can innovate and perform their many functions better and more efficiently.

In this roundtable discussion, Steve Gens, Remco Munnik and James Kelleher explore the potential and the practicalities of building future processes on a single, joined-up content platform.

New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.

A coalition of data, computational power, and AI is bringing the full potential of in silico medicine out of the realm of science fiction.

The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.

Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.

Recruitment of data scientists is much more than a numbers game.

How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.

The European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.

Pratap Khedkar, managing principal for ZS’ global pharmaceuticals practice, talks to Pharm Exec about what companies need to focus on to achieve and optimize digital transformation in 2021 and beyond.

With the UK maintaining a world-leading position in key areas of technology, 2021 could be a banner year for its life sciences.

Melissa Fellner of AstraZeneca and Leonie Goddard of Veeva, talk to Pharm Exec about how AZ’s mission to transform its digital strategies to better connect with customers.

Key takeaways on digital health from the 2021 JP Morgan Healthcare conference.

Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.

Exploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.